ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO959

Patient-Reported Outcomes in a Real-World Study of Anemia of CKD in the Middle East and Africa

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Arici, Mustafa, Hacettepe University Faculty of Medicine, Ankara, Turkey
  • Al-Ghamdi, Saeed, King Abdulaziz University, Jeddah, Saudi Arabia
  • Assounga, Alain Guy Honoré, University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa
  • El-Koraie, Ahmed, Alexandria University, Alexandria, Egypt
  • Mcmillan, Abigail, Adelphi Real World, Bollington, Cheshire East, United Kingdom
  • Sumarsono, Budiwan, Astellas Pharma Singapore Pte Ltd, Singapore, Singapore
  • Blogg, Martin, Astellas Pharma Europe Ltd, Addlestone, Surrey, United Kingdom
  • Ng, Daniel Bin, Astellas Pharma Singapore Pte Ltd, Singapore, Singapore
  • Lansang, Elvira, Astellas Pharma Singapore Pte Ltd, Singapore, Singapore

Anemia is a common complication of chronic kidney disease (CKD) that can negatively impact quality of life. Treatment satisfaction of patients with anemia of CKD living in the Middle East or Africa was explored.


SATISFY was a real-world study in Egypt, Saudi Arabia, South Africa and Turkey (1 Jun–1 Sep 2022). Physicians and patients completed cross-sectional surveys of treatment perceptions; patients’ clinical characteristics were recorded via retrospective review of medical records. Eligible physicians were nephrologists with ≥1 year of experience. Eligible patients were aged ≥18 years with CKD stage 3b–5 at anemia diagnosis and ≥2 years of follow-up data. Data were analyzed descriptively.


In total, 217 physicians and 766 patients (457 [60%] non-dialysis dependent; 286 [37%] dialysis dependent; 23 missing [3%] at data extraction) completed surveys. Mean patient age (standard deviation) was 48 (14) years; 457 (60%) were male. Treatment satisfaction was high (89% of physicians and 84% of treated patients [n=478] were satisfied/very satisfied). Overall, 24% of treated patients had severe-to-very severe anemia symptoms, 15% reported worsening symptoms since initiating most recent treatment and 38% had quite-to-very bothersome side-effects (Figure). Over 80% of both patients and physicians reported that physicians made the final treatment decisions.


Despite high treatment satisfaction, patients with anemia of CKD in the Middle East and Africa reported high symptom burden, treatment side-effects and worsening of symptoms, suggesting a high unmet need.


  • Commercial Support – Astellas Pharma Singapore Pte Ltd.